B-intervention	0	9	Bupropion
O	10	13	for
O	14	21	control
O	22	24	of
B-condition	25	28	hot
I-condition	29	36	flashes
O	37	39	in
O	40	46	breast
O	47	53	cancer
O	54	63	survivors
O	63	64	:
O	65	66	a
O	67	78	prospective
O	78	79	,
O	80	86	double
O	86	87	-
O	87	92	blind
O	92	93	,
O	94	104	randomized
O	104	105	,
O	106	115	crossover
O	115	116	,
O	117	122	pilot
O	123	128	phase
O	129	131	II
O	132	137	trial
O	137	138	.

O	139	142	Hot
O	143	150	flashes
O	151	152	(
O	152	155	HFs
O	155	156	)
O	157	160	and
O	161	167	sexual
O	168	179	dysfunction
O	180	185	often
O	186	192	affect
O	193	199	breast
O	200	206	cancer
O	207	208	(
O	208	210	BC
O	210	211	)
O	212	221	survivors
O	222	225	and
O	226	236	compromise
O	237	242	their
O	243	250	quality
O	251	253	of
O	254	258	life
O	258	259	.

O	260	269	Bupropion
O	270	272	is
O	273	275	an
O	276	290	antidepressive
O	291	301	medication
O	302	306	used
O	307	310	for
O	311	318	smoking
O	319	328	cessation
O	329	332	and
O	333	337	also
O	338	341	has
O	342	346	been
O	347	357	previously
O	358	365	studied
O	366	369	for
O	370	373	the
O	374	383	treatment
O	384	386	of
O	387	393	sexual
O	394	405	dysfunction
O	405	406	.

O	407	409	We
O	410	415	aimed
O	416	418	to
O	419	427	evaluate
O	428	437	bupropion
O	437	438	'
O	438	439	s
O	440	448	efficacy
O	449	451	in
O	452	463	controlling
O	464	467	HFs
O	468	470	in
O	471	473	BC
O	474	483	survivors
O	483	484	.

O	485	489	This
O	490	493	was
O	494	495	a
O	496	506	randomized
O	506	507	,
O	508	514	double
O	514	515	-
O	515	520	blind
O	520	521	,
O	522	531	crossover
O	531	532	,
O	533	540	placebo
O	540	541	-
O	541	551	controlled
O	552	557	pilot
O	558	563	study
O	564	568	that
O	569	577	enrolled
B-total-participants	578	580	55
B-eligibility	581	583	BC
I-eligibility	584	593	survivors
I-eligibility	594	597	who
I-eligibility	598	606	reported
I-eligibility	607	611	more
I-eligibility	612	616	than
I-eligibility	617	622	seven
I-eligibility	623	626	HFs
I-eligibility	627	630	per
I-eligibility	631	635	week
O	635	636	.

O	637	645	Subjects
O	646	650	were
O	651	661	randomized
O	662	664	to
O	665	672	receive
O	673	679	either
O	680	689	bupropion
O	690	695	150mg
O	696	701	twice
O	702	707	daily
O	708	711	for
O	712	716	four
O	717	722	weeks
O	723	731	followed
O	732	734	by
O	735	738	one
O	739	743	week
O	744	746	of
O	747	754	washout
O	755	758	and
O	759	763	four
O	764	768	more
O	769	774	weeks
O	775	777	of
B-control	778	785	placebo
O	786	791	twice
O	792	797	daily
O	798	800	or
O	801	805	vice
O	806	811	versa
O	811	812	.

O	813	816	The
O	817	824	primary
O	825	828	end
O	829	834	point
O	835	838	was
B-outcome-Measure	839	846	average
I-outcome-Measure	847	852	daily
I-outcome-Measure	853	855	HF
I-outcome-Measure	856	864	activity
O	865	866	(
O	866	872	number
O	873	875	of
O	876	879	HFs
O	880	883	and
O	884	885	a
O	886	891	score
O	892	901	combining
O	902	908	number
O	909	912	and
O	913	921	severity
O	921	922	)
O	923	931	reported
O	932	937	while
O	938	940	on
O	941	950	bupropion
O	951	953	or
O	954	956	on
O	957	964	placebo
O	964	965	.

O	966	975	Secondary
O	976	979	end
O	980	986	points
O	987	991	were
B-outcome-Measure	992	998	sexual
I-outcome-Measure	999	1010	dysfunction
O	1010	1011	,
B-outcome-Measure	1012	1022	depression
O	1022	1023	,
O	1024	1027	and
B-outcome-Measure	1028	1035	quality
I-outcome-Measure	1036	1038	of
I-outcome-Measure	1039	1043	life
O	1044	1053	evaluated
O	1054	1058	with
O	1059	1062	the
O	1063	1070	Arizona
O	1071	1077	Sexual
O	1078	1088	Experience
O	1089	1094	Scale
O	1094	1095	,
O	1096	1100	Beck
O	1101	1111	Depression
O	1112	1121	Inventory
O	1121	1122	,
O	1123	1126	and
O	1127	1135	European
O	1136	1148	Organization
O	1149	1152	for
O	1153	1161	Research
O	1162	1165	and
O	1166	1175	Treatment
O	1176	1178	of
O	1179	1185	Cancer
O	1186	1193	Quality
O	1194	1196	of
O	1197	1201	Life
O	1202	1215	Questionnaire
O	1215	1216	-
O	1216	1219	C30
O	1219	1220	,
O	1221	1233	respectively
O	1233	1234	.

O	1235	1244	Bupropion
O	1245	1252	reduced
B-outcome	1253	1256	HFs
O	1257	1259	by
B-iv-cont-mean	1260	1261	1
I-iv-cont-mean	1261	1262	.
I-iv-cont-mean	1262	1264	26
I-iv-cont-mean	1265	1268	per
I-iv-cont-mean	1269	1272	day
O	1273	1276	and
O	1277	1280	the
B-outcome	1281	1283	HF
I-outcome	1284	1289	score
O	1290	1292	by
B-iv-bin-percent	1293	1294	6
I-iv-bin-percent	1294	1295	.
I-iv-bin-percent	1295	1297	31
I-iv-bin-percent	1297	1298	%
O	1298	1299	,
O	1300	1307	whereas
O	1308	1315	placebo
O	1316	1323	reduced
B-outcome	1324	1327	HFs
O	1328	1330	by
B-cv-cont-mean	1331	1332	2
I-cv-cont-mean	1332	1333	.
I-cv-cont-mean	1333	1335	11
I-cv-cont-mean	1336	1339	per
I-cv-cont-mean	1340	1343	day
O	1344	1345	(
O	1345	1346	P
O	1346	1347	>
O	1347	1348	0
O	1348	1349	.
O	1349	1351	05
O	1351	1352	)
O	1353	1356	and
O	1357	1360	the
B-outcome	1361	1363	HF
I-outcome	1364	1369	score
O	1370	1372	by
B-cv-bin-percent	1373	1375	30
I-cv-bin-percent	1375	1376	.
I-cv-bin-percent	1376	1378	47
I-cv-bin-percent	1378	1379	%
O	1380	1381	(
O	1381	1382	P
O	1382	1383	>
O	1383	1384	0
O	1384	1385	.
O	1385	1387	05
O	1387	1388	)
O	1388	1389	.

O	1390	1395	There
O	1396	1400	were
O	1401	1403	no
O	1404	1417	statistically
O	1418	1429	significant
O	1430	1441	differences
O	1442	1449	between
O	1450	1459	bupropion
O	1460	1463	and
O	1464	1471	placebo
O	1472	1474	in
O	1475	1478	the
B-outcome	1479	1486	Arizona
I-outcome	1487	1493	Sexual
I-outcome	1494	1504	Experience
I-outcome	1505	1510	Scale
O	1510	1511	,
B-outcome	1512	1516	Beck
I-outcome	1517	1527	Depression
I-outcome	1528	1537	Inventory
O	1537	1538	,
O	1539	1542	and
O	1543	1551	European
O	1552	1564	Organization
O	1565	1568	for
O	1569	1577	Research
O	1578	1581	and
O	1582	1591	Treatment
O	1592	1594	of
O	1595	1601	Cancer
B-outcome	1602	1609	Quality
I-outcome	1610	1612	of
I-outcome	1613	1617	Life
O	1618	1631	Questionnaire
O	1631	1632	-
O	1632	1635	C30
O	1635	1636	.

O	1637	1639	At
O	1640	1643	the
O	1644	1647	end
O	1648	1650	of
O	1651	1654	the
O	1655	1660	study
O	1660	1661	,
B-iv-bin-percent	1662	1664	47
I-iv-bin-percent	1664	1665	%
O	1666	1668	of
O	1669	1672	the
B-outcome	1673	1681	patients
I-outcome	1682	1691	preferred
I-outcome	1692	1701	bupropion
O	1701	1702	,
O	1703	1710	whereas
B-cv-bin-percent	1711	1713	53
I-cv-bin-percent	1713	1714	%
B-outcome	1715	1724	preferred
I-outcome	1725	1732	placebo
O	1732	1733	.

O	1734	1739	There
O	1740	1744	were
O	1745	1747	no
O	1748	1761	statistically
O	1762	1773	significant
O	1774	1785	differences
O	1786	1788	in
O	1789	1793	side
O	1794	1801	effects
O	1802	1809	between
O	1810	1813	the
O	1814	1819	study
O	1820	1826	groups
O	1826	1827	.

O	1828	1836	Compared
O	1837	1841	with
O	1842	1849	placebo
O	1849	1850	,
O	1851	1860	bupropion
O	1861	1864	did
O	1865	1868	not
O	1869	1876	control
O	1877	1880	HFs
O	1881	1883	in
O	1884	1888	this
O	1889	1894	group
O	1895	1897	of
O	1898	1900	BC
O	1901	1910	survivors
O	1910	1911	.
